Chemistry Vice President at GlaxoSmithKline
Raleigh-Durham, North Carolina Area
Chemistry Vice President at GlaxoSmithKline
Raleigh-Durham, North Carolina Area
All of my professional experience has been in the science of drug discovery starting as a synthetic organic chemist and slowly broadening my role to a chemistry team leader, project leader, department head, international director and now, in my current role of Molecular Discovery Research Chemistry VP. I was fortunate to be able to contribute to many meaningful drug discovery projects, but my main interests have been in infectious diseases and oncology. With some amazing co-authors, I have been able to write or contribute to over 70 peer-reviewed journal articles & patents, and edit one recently finished book called "Gene Family Targeted Molecular Design" (Wiley).
drug design, scientific strategy for a portfolio of drug discovery projects, kinase signaling inhibition
(Public Company; 10,001 or more employees; GSK; Pharmaceuticals industry)
June 2007 — Present (2 years 6 months)
Advanced through increasingly responsible capacities at the world’s second-largest pharmaceutical developer and manufacturer, culminating in current role with global accountability for pioneering Exploratory Chemistry in support of all therapeutically focused Centers of Excellence in Drug Discovery, and for the chemistry strategy to design and implement compound collection enhancement to support all screening events and new technologies.
(Public Company; 10,001 or more employees; GSK; Pharmaceuticals industry)
January 2001 — June 2007 (6 years 6 months)
Responsible for building scientific teams in North Carolina, USA; Stevenage, UK; Tsukuba, Japan and directing scientific strategy in the Kinases, Enzymes, Ion Channels, and Cellular Pathways medicinal chemistry research areas with the objective of providing multiple chemical series for targets in the early-stage drug discovery portfolio covering 11 therapeutic areas.
(Public Company; 10,001 or more employees; GSK; Pharmaceuticals industry)
1995 — 2001 (6 years )
As ErbB2 Research Team Leader, formulated a medicinal chemistry strategy that led to the selection of the GW2016 drug candidate, which, following positive Phase III results in breast cancer indications, launched in 1Q07 as TykerbTM; managed transatlantic team of scientists with specialties in enzymology, drug metabolism, development chemistry, cancer biology, research chemistry, formulations, toxicology, secondary pharmacology and intellectual property.
(Public Company; 10,001 or more employees; Pharmaceuticals industry)
February 1989 — June 1995 (6 years 5 months)
(Public Company; 10,001 or more employees; PFE; Pharmaceuticals industry)
1985 — 1989 (4 years )
Organic Chemistry
new technology in drug discovery, new ideas for building a corporate compound collection, target class work especially in emerging areas such as stem cell work, epigenetics, ubiquitins signaling, etc., Marathons, running and cycling events, ballroom dancing, golf
American Association for Cancer Research, Chemists in Cancer Research, American Chemical Society
American Chemical Society Heroes of Chemistry, 2008
American Chemical Society’s 59th Southeastern Regional Industrial Innovation Award, October 2007